AbbVie sees Q1 adjusted EPS with expenses $2.34-$2.38, consensus $2.51

In a regulatory filing, AbbVie (ABBV) disclosed that reported GAAP earnings and adjusted non-GAAP earnings for the first quarter of 2025 are expected to include acquired IPR&D and milestones expense of $248M on a pre-tax basis, representing an unfavorable impact of 13c to both GAAP diluted earnings per share and adjusted non-GAAP diluted earnings per share. “Results for the quarter ended March 31, 2025 have not been finalized and are subject to our financial statement closing procedures. There can be no assurance that our final results will not differ from these preliminary estimates. While acquired IPR&D and milestones expense may be incurred upon execution of collaborations, licensing agreements, and other asset acquisitions, AbbVie does not forecast acquired IPR&D and milestones expense due to uncertainty of the future occurrence and timing of these transactions. Adjusted diluted earnings per share guidance for 2025 previously announced on January 31, 2025 excluded the impact of acquired IPR&D and milestones expense that may be incurred in 2025. AbbVie’s full-year 2025 adjusted diluted earnings per share guidance range, including the impact of first quarter 2025 acquired IPR&D and milestones expense, is $11.99-$12.19. AbbVie’s first quarter 2025 adjusted diluted earnings per share guidance range, including the impact of first quarter 2025 acquired IPR&D and milestones expense, is $2.34 – $2.38. This guidance does not reflect the impact related to AbbVie and Gubra’s licensing agreement to develop GUB014295, as that transaction closed after the first quarter of 2025,” the company stated.